Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Clark

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Developing World Bioethics|April 12, 2014
Reuse Of Pacemakers In Ghana And Nigeria: Medical, Legal, Cultural And Ethical PerspectivesAloysius Ochasi, Peter Clark
Thrombosis Research|February 17, 2009
North American and British guidelines for anti-thrombotic therapy: are we reaching consensus?Peter Clark, Shannon M Bates
Seminars in Thrombosis and Hemostasis|April 24, 2003
Prevention and treatment of arterial thrombosis in pregnancyPeter Clark, Ian A Greer
Intensive Care Medicine|November 12, 2005
Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et alGareth L Thomas, Peter Clark
Health Progress (Saint Louis, Mo.)|May 31, 2007
Regaining minorities' trust. A clinic project in a Philadelphia neighborhood may serve as a paradigm for Catholic hospitalsPeter Clark, Megan Brown, Mathew Mathew
Journal of Clinical Pathology|November 26, 2010
Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequenceStephen Hayes, Sajad Ahmed, Peter Clark
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosisKay Nolan, Helen Knight, Peter Clark
The Lancet. Oncology|September 20, 2011
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancerFiona Rinaldi, Elisabeth George, Peter Clark
Current Opinion in Oncology|March 11, 2017
New developments in the management of nonmuscle invasive bladder cancerMark D Tyson, Daniel Lee, Peter Clark
The Lancet. Oncology|October 2, 2012
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancerBernice Dillon, Bhash Naidoo, Helen Knight, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Developing World Bioethics|April 12, 2014
Reuse Of Pacemakers In Ghana And Nigeria: Medical, Legal, Cultural And Ethical PerspectivesAloysius Ochasi, Peter Clark
Thrombosis Research|February 17, 2009
North American and British guidelines for anti-thrombotic therapy: are we reaching consensus?Peter Clark, Shannon M Bates
Seminars in Thrombosis and Hemostasis|April 24, 2003
Prevention and treatment of arterial thrombosis in pregnancyPeter Clark, Ian A Greer
Intensive Care Medicine|November 12, 2005
Comment on "Early treatment with activated protein C for meningococcal septic shock: case report and literature review" by Hasin et alGareth L Thomas, Peter Clark
Health Progress (Saint Louis, Mo.)|May 31, 2007
Regaining minorities' trust. A clinic project in a Philadelphia neighborhood may serve as a paradigm for Catholic hospitalsPeter Clark, Megan Brown, Mathew Mathew
Journal of Clinical Pathology|November 26, 2010
Immunohistochemical assessment for Cdx2 expression in the Barrett metaplasia-dysplasia-adenocarcinoma sequenceStephen Hayes, Sajad Ahmed, Peter Clark
The Lancet. Respiratory Medicine|January 17, 2014
NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosisKay Nolan, Helen Knight, Peter Clark
The Lancet. Oncology|September 20, 2011
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancerFiona Rinaldi, Elisabeth George, Peter Clark
Current Opinion in Oncology|March 11, 2017
New developments in the management of nonmuscle invasive bladder cancerMark D Tyson, Daniel Lee, Peter Clark
The Lancet. Oncology|October 2, 2012
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancerBernice Dillon, Bhash Naidoo, Helen Knight, et al.
Pageof 10